» Articles » PMID: 16085715

Cyclin-dependent Kinase (CDK) Phosphorylation Destabilizes Somatic Wee1 Via Multiple Pathways

Overview
Specialty Science
Date 2005 Aug 9
PMID 16085715
Citations 107
Authors
Affiliations
Soon will be listed here.
Abstract

At the onset of M phase, the activity of somatic Wee1 (Wee1A), the inhibitory kinase for cyclin-dependent kinase (CDK), is down-regulated primarily through proteasome-dependent degradation after ubiquitination by the E3 ubiquitin ligase SCF(beta-TrCP). The F-box protein beta-TrCP (beta-transducin repeat-containing protein), the substrate recognition component of the ubiquitin ligase, binds to its substrates through a conserved binding motif (phosphodegron) containing two phosphoserines, DpSGXXpS. Although Wee1A lacks this motif, phosphorylation of serines 53 and 123 (S53 and S123) of Wee1A by polo-like kinase 1 (Plk1) and CDK, respectively, are required for binding to beta-TrCP. The sequence surrounding phosphorylated S53 (DpSAFQE) is similar to the conserved beta-TrCP-binding motif; however, the role of S123 phosphorylation (EEGFGSSpSPVK) in beta-TrCP binding was not elucidated. In the present study, we show that phosphorylation of S123 (pS123) by CDK promoted the binding of Wee1A to beta-TrCP through three independent mechanisms. The pS123 not only directly interacted with basic residues in the WD40 repeat domain of beta-TrCP but also primed phosphorylation by two independent protein kinases, Plk1 and CK2 (formerly casein kinase 2), to create two phosphodegrons on Wee1A. In the case of Plk1, S123 phosphorylation created a polo box domain-binding motif (SpSP) on Wee1A to accelerate phosphorylation of S53 by Plk1. CK2 could phosphorylate S121, but only if S123 was phosphorylated first, thereby generating the second beta-TrCP-binding site (EEGFGpS121). Using a specific inhibitor of CK2, we showed that the phosphorylation-dependent degradation of Wee1A is important for the proper onset of mitosis.

Citing Articles

N-Glycoside of Indolo[2,3-]pyrrolo[3,4-]carbazole LCS1269 Exerts Anti-Glioblastoma Effects by G2 Cell Cycle Arrest and CDK1 Activity Modulation: Molecular Docking Studies, Biological Investigations, and ADMET Prediction.

Kalitin N, Koroleva N, Lushnikova A, Babaeva M, Samoylenkova N, Savchenko E Pharmaceuticals (Basel). 2025; 17(12.

PMID: 39770484 PMC: 11676706. DOI: 10.3390/ph17121642.


The Potential for Targeting G/M Cell Cycle Checkpoint Kinases in Enhancing the Efficacy of Radiotherapy.

Melia E, Parsons J Cancers (Basel). 2024; 16(17).

PMID: 39272874 PMC: 11394570. DOI: 10.3390/cancers16173016.


Elevating PLK1 overcomes BETi resistance in prostate cancer via triggering BRD4 phosphorylation-dependent degradation in mitosis.

Zhang Y, Fong K, Mao F, Wang R, Allison D, Napier D Cell Rep. 2024; 43(7):114431.

PMID: 38968071 PMC: 11334074. DOI: 10.1016/j.celrep.2024.114431.


Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia.

Malyukova A, Lahnalampi M, Falques-Costa T, Polonen P, Sipola M, Mehtonen J Genome Biol. 2024; 25(1):143.

PMID: 38822412 PMC: 11143599. DOI: 10.1186/s13059-024-03260-4.


A new wave of innovations within the DNA damage response.

Li Q, Qian W, Zhang Y, Hu L, Chen S, Xia Y Signal Transduct Target Ther. 2023; 8(1):338.

PMID: 37679326 PMC: 10485079. DOI: 10.1038/s41392-023-01548-8.


References
1.
Lee K, Yuan Y, Kuriyama R, Erikson R . Plk is an M-phase-specific protein kinase and interacts with a kinesin-like protein, CHO1/MKLP-1. Mol Cell Biol. 1995; 15(12):7143-51. PMC: 230970. DOI: 10.1128/MCB.15.12.7143. View

2.
Neef R, Preisinger C, Sutcliffe J, Kopajtich R, Nigg E, Mayer T . Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis. J Cell Biol. 2003; 162(5):863-75. PMC: 2172827. DOI: 10.1083/jcb.200306009. View

3.
Lane H, Nigg E . Cell-cycle control: POLO-like kinases join the outer circle. Trends Cell Biol. 1997; 7(2):63-8. DOI: 10.1016/S0962-8924(96)10051-9. View

4.
Sakchaisri K, Asano S, Yu L, Shulewitz M, Park C, Park J . Coupling morphogenesis to mitotic entry. Proc Natl Acad Sci U S A. 2004; 101(12):4124-9. PMC: 384705. DOI: 10.1073/pnas.0400641101. View

5.
Wu G, Xu G, Schulman B, Jeffrey P, Harper J, Pavletich N . Structure of a beta-TrCP1-Skp1-beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin ligase. Mol Cell. 2003; 11(6):1445-56. DOI: 10.1016/s1097-2765(03)00234-x. View